Protective Effects of Notoginsenoside R1 via Regulation of the PI3K-Akt-mTOR/JNK Pathway in Neonatal Cerebral Hypoxic-Ischemic Brain Injury.

Abstract

Notoginsenoside R1 (NGR1) is a predominant phytoestrogen extracted from Panax notoginseng that has recently been reported to play important roles in the treatment of cardiac dysfunction, diabetic kidney disease, and acute liver failure. Studies have suggested that NGR1 may be a viable treatment of hypoxic-ischemic brain damage (HIBD) in neonates by reducing endoplasmic reticulum stress via estrogen receptors (ERs). However, whether NGR1 has other neuroprotective mechanisms or long-term neuroprotective effects is unclear. In this study, oxygen-glucose deprivation/reoxygenation (OGD/R) in primary cortical neurons and unilateral ligation of the common carotid artery (CCL) in 7-day-old postnatal Sprague Dawley (SD) rats followed by exposure to a hypoxic environment were used to mimic an HIBD episode. We assessed the efficacy of NGR1 by measuring neuronal damage with MTT assay and assessed brain injury by TTC staining and brain water content detection 24-48 h after OGD/HIE. Simultaneously, we measured the long-term neurophysiological effects using the beam walking test (5 weeks after HI) and Morris water maze test 5-6 weeks after HI. Expression of PI3K-Akt-mTOR/JNK (24 h after HI or OGD/R) proteins was detected by Western blotting after stimulation with HI, NGR1, LY294002 (PI3K inhibitor), 740Y-P (PI3K agonist), or ICI 182780(estrogen receptors inhibitor). The results indicated that NGR1 exerted neuroprotective effects by inhibiting neuronal apoptosis and promoting cell survival via the PI3K-Akt-mTOR/JNK signaling pathways by targeting ER in neonatal hypoxic-ischemic injury.

• Authors: Liu Tu, Yan Wang, Di Chen, Ping Xiang, Jingjing Shen, Yingbo Li, Shali Wang
• Journal: Neurochemical research (Neurochem Res) Vol. 43 Issue 6 Pg. 1210-1226 (Jun 2018) ISSN: 1573-6903 [Electronic] United States
• PMID: 29696512 (Publication Type: Journal Article)

Chemical References

• Ginsenosides
• Neuroprotective Agents
• mTOR protein, rat
• Proto-Oncogene Proteins c-akt
• TOR Serine-Threonine Kinases
• notoginsenoside R1

Topics

• Animals
• Animals, Newborn
• Cells, Cultured
• Ginsenosides (pharmacology, therapeutic use)
• Hypoxia-Ischemia, Brain (metabolism, prevention & control)
• MAP Kinase Signaling System (drug effects, physiology)
• Male
• Neuroprotective Agents (pharmacology, therapeutic use)
• Phosphatidylinositol 3-Kinases (biosynthesis)
• Proto-Oncogene Proteins c-akt (biosynthesis)
• Rats
• Rats, Sprague-Dawley
• TOR Serine-Threonine Kinases (biosynthesis)